ECSP099192A - SPECIFIC HUMAN MONOCLONAL ANTIBODIES FOR HUMAN LIGHT ANTAGONISTS - Google Patents

SPECIFIC HUMAN MONOCLONAL ANTIBODIES FOR HUMAN LIGHT ANTAGONISTS

Info

Publication number
ECSP099192A
ECSP099192A ECSP099192A ECSP099192A EC SP099192 A ECSP099192 A EC SP099192A EC SP099192 A ECSP099192 A EC SP099192A EC SP099192 A ECSP099192 A EC SP099192A
Authority
EC
Ecuador
Prior art keywords
hlight
antibodies
fully human
polypeptide
immunospecifically
Prior art date
Application number
Other languages
Spanish (es)
Inventor
Steven Granger
Shinichiro Kato
Carl F Ware
Original Assignee
Kyowa Hakko Kirin Co Ltd
La Jolla Institute For Allergy And Immunology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co Ltd, La Jolla Institute For Allergy And Immunology filed Critical Kyowa Hakko Kirin Co Ltd
Publication of ECSP099192A publication Critical patent/ECSP099192A/en

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se proporcionan aquí anticuerpos, como por ejemplo anticuerpos totalmente humanos, que se unen inmunoespecíficamente a un polipéptido hLIGHT. Se proporcionan también ácidos nucleicos aislados que codifican anticuerpos, como por ejemplo anticuerpos totalmente humanos que se unen inmunoespecíficamente a un polipéptido hLIGHT. Se proporcionan además vectores y células hospederas que comprenden anticuerpos que codifican ácidos nucleicos, como por ejemplo anticuerpos totalmente humanos, que se unen inmunoespecíficamente a un polipéptido hLIGHT. Se proporcionan también métodos para preparar anticuerpos, como por ejemplo anticuerpos totalmente humanos, que se unen inmunoespecíficamente a un polipéptido hLIGHT. Se proporciona también aquí un método para tratar una enfermedad mediada por hLIGHT en un sujeto, que comprende la administración al sujeto de un anticuerpo, como por ejemplo un anticuerpo totalmente humano, que se une inmunoespecíficamente a un polipéptido hLIGHT. En modalidades preferidas, los anticuerpos anti-hLIGHT proporcionados aquí mejoran, neutralizan o inhiben de otra forma la actividad biológica hLIGHT in vivo (por ejemplo, la producción o secreción mediada por hLIGHT de CCL20, IL-8 o RANTES a partir de una célula que expresa un receptor hLIGHT). Se proporciona también aquí un método para detectar hLIGHT en una muestra así como un método para mejorar, neutralizar o inhibir de otra forma la actividad hLIGHT, por ejemplo, en un sujeto humano que padece de una enfermedad en donde la actividad hLIGHT es perjudicial.Antibodies, such as fully human antibodies, which bind immunospecifically to an hLIGHT polypeptide are provided herein. Isolated nucleic acids encoding antibodies are also provided, such as fully human antibodies that immunospecifically bind to an hLIGHT polypeptide. In addition, vectors and host cells comprising antibodies encoding nucleic acids, such as fully human antibodies, that bind immunospecifically to an hLIGHT polypeptide are provided. Methods for preparing antibodies, such as fully human antibodies, that bind immunospecifically to an hLIGHT polypeptide are also provided. A method is also provided here for treating a hLIGHT mediated disease in a subject, which comprises administering to the subject an antibody, such as a fully human antibody, that binds immunospecifically to an hLIGHT polypeptide. In preferred embodiments, the anti-hLIGHT antibodies provided herein enhance, neutralize or otherwise inhibit hLIGHT biological activity in vivo (eg, hLIGHT-mediated production or secretion of CCL20, IL-8 or RANTES from a cell that expresses an hLIGHT receiver). A method is also provided here to detect hLIGHT in a sample as well as a method to improve, neutralize or otherwise inhibit hLIGHT activity, for example, in a human subject suffering from a disease where hLIGHT activity is detrimental.

ECSP099192 2006-08-28 2009-03-19 SPECIFIC HUMAN MONOCLONAL ANTIBODIES FOR HUMAN LIGHT ANTAGONISTS ECSP099192A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84077406P 2006-08-28 2006-08-28

Publications (1)

Publication Number Publication Date
ECSP099192A true ECSP099192A (en) 2009-06-30

Family

ID=41057664

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP099192 ECSP099192A (en) 2006-08-28 2009-03-19 SPECIFIC HUMAN MONOCLONAL ANTIBODIES FOR HUMAN LIGHT ANTAGONISTS

Country Status (6)

Country Link
CN (1) CN101663321B (en)
EC (1) ECSP099192A (en)
HN (1) HN2009000414A (en)
SI (1) SI2292663T1 (en)
UA (1) UA99714C2 (en)
ZA (1) ZA200901165B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201701194D0 (en) * 2017-01-24 2017-03-08 Capella Bioscience Ltd Antigen binding molecules that bind light
EP4126945A4 (en) * 2020-04-01 2024-02-28 Avalo Therapeutics, Inc. Methods and treatment involving excess free light

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010015817A (en) * 1997-11-14 2001-02-26 유로-셀티큐 에스.에이. Modified Antibodies with Enhanced Ability to elicit an anti-idiotype response

Also Published As

Publication number Publication date
UA99714C2 (en) 2012-09-25
CN101663321A (en) 2010-03-03
HN2009000414A (en) 2012-02-17
CN101663321B (en) 2014-10-08
SI2292663T1 (en) 2014-02-28
ZA200901165B (en) 2010-06-30

Similar Documents

Publication Publication Date Title
NI200900027A (en) HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO LIGHT HUMAN ANTAGONISTS.
AR073978A1 (en) HIGH AFFINITY HUMAN ANTIBODIES FOR THE IL-4-HUMAN RECEIVER
EA202192103A1 (en) ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS SPECIFIC TO ORPHAN RECEPTOR TYPE OF RECEPTOR TYROSINE KINASE 1 (ROR1)
EA200970477A1 (en) HUMAN MONOCLONAL ANTIBODIES TO BTLA AND METHODS OF APPLICATION
EA201001139A1 (en) IMPROVED ANTIBODY ANTI-TrkB
EA200701292A1 (en) COMPOSITIONS CONTAINING ANTIBODIES AGAINST THE IGF-1 RECEPTOR AND WAYS TO OBTAIN ANTIBODIES
BR112012007860A2 (en) "siglec 15 antibodies in the treatment of bone loss disease"
BR112012018914A2 (en) "humanized antibody, antigen binding protein, nucleic acid molecule, expression vector, recombinant host cell, antibody or antigen binding protein, methods for producing an antigen binding protein and for treating a subject affected by an autoimmune or inflammatory disease, and, pharmaceutical composition. "
RU2017107773A (en) ANTIBODIES SPECIFIC TO MMP9
BRPI0607315A2 (en) isolated polynucleotide, expression vector, composition, method of producing an antigen binding molecule, antigen binding molecule and the use thereof, method for detecting in vivo or in vitro the presence of egfr in a sample, engineered host cell , pharmaceutical composition and its use
BR112012003064B8 (en) antibody or antigen-binding fragment thereof, combination comprising them, method of detecting rsv infection, nucleic acid molecules, and method of producing an antibody or antigen-binding fragment thereof
EA201591131A1 (en) DNA STRUCTURE ANTIBODY AND METHOD OF THEIR APPLICATION
ECSP12011698A (en) CEA ANTIBODIES
EA200901436A1 (en) Antigen-binding proteins that bind PAR-2
MA32982B1 (en) Binding proteins to human cgrp receptors
EA201490825A1 (en) TDP-43-SPECIFICALLY BINDING MOLECULES
UA115439C2 (en) Humanized antibodies that recognize alpha-synuclein
EA201101516A1 (en) ANTIBODIES SPECIFIC FOR KADGERINA-17
FR2933773B1 (en) METHOD FOR DETERMINING THE ISOMERASE DISULFIDE PROTEIN FOR IN VITRO DIAGNOSIS OF COLORECTAL CANCER
UA114108C2 (en) Monoclonal antibodies for use in diagnosis and therapy of cancers and autoimmune disease
GB201003701D0 (en) System for the expression of a protein
UA118646C2 (en) Human oncostatin m antibodies and methods of use
ATE535546T1 (en) HUMAN MONOCLONAL ANTIBODIES THAT BIND SPECIFICALLY TO IFG-II
Karlsen et al. The proteomic profile of the human myotendinous junction
EA202091569A1 (en) MONOCLONAL ANTIBODIES AND METHODS OF THEIR APPLICATION